Vered Caplan

President, Chief Executive Officer and Chairperson

Vered Caplan has been the Chief Executive Officer since August 14, 2014, prior to which she was Interim President and CEO since December 23, 2013. Since 2008, Ms. Caplan has been Chief Executive Officer of Kamedis Ltd., a company focused on utilizing plant extracts for dermatology purposes. From 2004 to 2007, Ms. Caplan was Chief Executive Officer of GammaCan International Inc., a company focused on the use of immunoglobulins for treatment of cancer. During the previous five years, Ms. Caplan has been a director of the following companies: Opticul Ltd., a company involved with optic based bacteria classification; Inmotion Ltd., a company involved with self-propelled disposable colonoscopies; Nehora Photonics Ltd., a company involved with noninvasive blood monitoring; Ocure Ltd., a company involved with wound management; Eve Medical Ltd., a company involved with hormone therapy for Menopause and PMS; and Biotech Investment Corp., a company involved with prostate cancer diagnostics. Ms. Caplan has a M.Sc. in biomedical engineering from TelAviv University specializing in signal processing; management for engineers from TelAviv University specializing in business development; and a B.Sc. in mechanical engineering from the Technion-Israel Institute of Technology specialized in software and cad systems. We believe that Ms. Caplan's significant experience relating to our industry and a deep knowledge of our business, based on her many years of involvement with our company, makes her suitable to serve as a director of our company.

Neil Reithinger, CPA

Chief Financial Officer, Secretary, and Treasurer

Neil Reithinger was appointed Chief Financial Officer, Secretary and Treasurer on August 1, 2014. Mr. Reithinger is the Founder and President of Eventus Advisory Group, LLC, a private, CFO-services firm incorporated in Arizona, which specializes in capital advisory and SEC compliance for publicly-traded and emerging growth companies. He is also the President of Eventus Consulting, P.C., a registered CPA firm in Arizona. Prior to forming Eventus, Mr. Reithinger was COO & CFO from March 2009 to December 2009 of New Leaf Brands, Inc., a branded beverage company, CEO of Nutritional Specialties, Inc. from April 2007 to October 2009, a nationally distributed nutritional supplement company that was acquired by Nutraceutical International, Inc., Chairman, CEO, President and director of Baywood International, Inc. from January 1998 to March 2009, a publicly-traded nutraceutical company and Controller of Baywood International, Inc. from December 1994 to January 1998. Mr. Reithinger earned a B.S. in Accounting from the University of Arizona and is a Certified Public Accountant. He is a Member of the American Institute of Certified Public Accountants and the Arizona Society of Certified Public Accountants.

Frédéric Tonglet

General Manager, Orgenesis, Belgium

Mr Tonglet (Commercial Engineer) is the General Manager of Orgenesis in Belgium. He has a proven track record of success in finance and biotechnology industries over the last 25 years, with roles spanning commercial engineering, project management and governance. In 2015, he was appointed Member of the Management Committee of Swiss Life (Luxembourg) S.A. where he was responsible for the implementation of large scale international projects. In 2016, he joined Orgenesis’ MaSTherCell CDMO in the role of Chief Finance Officer with a focus on strengthening its financial reporting and structuring requirements. In 2018, acting as Governance Officer of Orgenesis Inc, he played a key role in the up-listing of Orgenesis to NASDAQ and its accompanying investor relations program. More recently, he played an pivotal role in the sales process of MaSTherCell.

Evan Fishman

Chief Financial Officer, Orgenesis LTD

Mr. Fishman has been CFO of Orgenesis LTD since April 2018. He has a wealth of financial, capital markets, and management experience from a range of global companies. Prior to his position with Orgenesis, he served as CFO of Immunovative Therapies; CFO and VP Operations of Minicom Advanced Technologies; and as Financial Controller of the NASDAQ-listed Electric Fuel. Evan holds Bachelor of Commerce and Bachelor of Accountancy degrees from the University of the Witwatersrand, Johannesburg, and a Masters in International Business Administration from the University of London, England. He is a South African Chartered Accountant and a member of the Israeli Institute of Certified Public Accountants.

Peter Molloy

Executive Vice President, Corporate Development

Peter Molloy joined Orgenesis as Executive Vice President, Corporate Development, in January 2019. Peter has nearly 25 years of creating, advising and investing in private and public companies, with a particular focus on the Healthcare Sector. Peter is the founder and a principle shareholder of Edison Group, where he was also CEO of the company. He spent 15 years building Edison into an international brand with a global team in excess of 100 people, recognized for its world class equity research platform, advisory services, and deep sector expertise. Peter is also the co-founder of various other companies including, most recently, a small molecule biotech, Tarus Therapeutics, focused on immuno-oncology. Peter’s earlier career includes a successful period as an institutional investor, most notably at Hermes Investment Management in London, managing a healthcare focused small/mid-cap portfolio, and with a close involvement in Hermes’ shareholder activism initiatives. Peter currently advises the Boards of several private and public companies, serves on the Board of Taronis Fuels, a publicly traded company in the US, and is also Chair of the African charity Kick4Life.

Efrat Assa-Kunik (PhD)

General Manager, Orgenesis Ltd.

Dr Assa-Kunik joined Orgenesis in 2016 as Head of Pre-Clinical Development. On 2017 she was appointed General Manager of Orgenesis Ltd and is responsible for providing R&D, regulatory, pre-clinical and clinical project management services for the Group. Dr Kunik earned her PhD at the Weizmann Institute of Science in the fields of genetics and developmental biology and a Masters from the Ben-Gurion University in immunology and cancer research. Additionally, Dr Kunik was a postdoctoral fellow at the Weizmann Institute in the department of neural biology. After her postdoc, Efrat joined BioGenCell, a clinical stage biotechnology company developing therapeutic cellular products from adult stem/progenitor cells, as a Senior Scientist. In 2012 she joined Pharmaseed, Israel’s leading GLP-certified pre-clinical CRO specializing in translational and regenerative studies and act as the director of the Business Development Unit, VP business development and manager of the business development activity in USA.